TSPAN32 and neoplasm: Given the limited success of GSIs as monotherapies due to toxicity and resistance [27,28,29,30,31], combining them with approaches that upregulate tumor-suppressive genes like TSPAN32 may provide a rational path toward improved treatment strategies.